Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study

Massimo Gentile, Fortunato Morabito, Giovanni Del Poeta, Francesca Romana Mauro, Gianluigi Reda, Paolo Sportoletti, Luca Laurenti, Marta Coscia, Yair Herishanu, Anna Grazia Recchia, Marzia Varettoni, Roberta Murru, Annalisa Chiarenza, Adalgisa Condoluci, Riccardo Moia, Daniela Pietrasanta, Giacomo Loseto, Ugo Consoli, Ilaria Scortechini, Francesca Maria RossiAntonella Zucchetto, Vincenzo Fraticelli, Ernesto Vigna, Cirino Botta, Giovanni Tripepi, Graziella D’ Arrigo, Angela Rago, Ilaria Angeletti, Annalisa Biagi, Ilaria Del Giudice, Riccardo Bomben, Gian Matteo Rigolin, Davide Rossi, Francesco Di Raimondo, Gianluca Gaidano, Aaron Polliack, Antonio Cuneo, Robin Foà, Valter Gattei

Research output: Contribution to journalArticle

Original languageEnglish
JournalLeukemia
DOIs
Publication statusAccepted/In press - Jan 1 2020

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Gentile, M., Morabito, F., Del Poeta, G., Mauro, F. R., Reda, G., Sportoletti, P., Laurenti, L., Coscia, M., Herishanu, Y., Recchia, A. G., Varettoni, M., Murru, R., Chiarenza, A., Condoluci, A., Moia, R., Pietrasanta, D., Loseto, G., Consoli, U., Scortechini, I., ... Gattei, V. (Accepted/In press). Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study. Leukemia. https://doi.org/10.1038/s41375-020-0833-x